Direction: Add one tablespoon into 150ml of water, Take before breakfast and night before bed
Clinical trials have shown that when they are combined with comprehensive lifestyle programs, these agents produce meaningful and sustained weight loss while improving obesity-related comorbidities, including T2DM and cardiovascular risk factors
Rare but serious events such as severe hypertension or cardiac incidents have been reported in case studies
and beinaglutide is a GLP-RA product developed by a Chinese company and was approved for marketing for the treatment of T2DM in China in September 2016.67 PEG-loxenatide, Chinas first long-acting GLP-RA product, was approved for marketing in China in May 2019.66 (Tables 1 and 2) GLP-1RAs , 1992 (John Enn) -4(exendin-4)
Approximately 76% of the trial population were White, 14% Asian, and 4% Black or African American